Suppr超能文献

神经性疼痛:临床医生实用指南

Neuropathic pain: a practical guide for the clinician.

作者信息

Gilron Ian, Watson C Peter N, Cahill Catherine M, Moulin Dwight E

机构信息

Department of Anesthesiology, Queen's University and Kingston General Hospital, Kingston, Ont.

出版信息

CMAJ. 2006 Aug 1;175(3):265-75. doi: 10.1503/cmaj.060146.

Abstract

Neuropathic pain, caused by various central and peripheral nerve disorders, is especially problematic because of its severity, chronicity and resistance to simple analgesics. The condition affects 2%-3% of the population, is costly to the health care system and is personally devastating to the people who experience it. The diagnosis of neuropathic pain is based primarily on history (e.g., underlying disorder and distinct pain qualities) and the findings on physical examination (e.g., pattern of sensory disturbance); however, several tests may sometimes be helpful. Important pathophysiologic mechanisms include sodium-and calcium-channel upregulation, spinal hyperexcitability, descending facilitation and aberrant sympathetic-somatic nervous system interactions. Treatments are generally palliative and include conservative nonpharmacologic therapies, drugs and more invasive interventions (e.g., spinal cord stimulation). Individualizing treatment requires consideration of the functional impact of the neuropathic pain (e.g., depression, disability) as well as ongoing evaluation, patient education, reassurance and specialty referral. We propose a primary care algorithm for treatments with the most favourable risk-benefit profile, including topical lidocaine, gabapentin, pregabalin, tricyclic antidepressants, mixed serotonin-norepinephrine reuptake inhibitors, tramadol and opioids. The field of neuropathic pain research and treatment is in the early stages of development, with many unmet goals. In coming years, several advances are expected in the basic and clinical sciences of neuropathic pain, which will provide new and improved therapies for patients who continue to experience this disabling condition.

摘要

由各种中枢和外周神经疾病引起的神经性疼痛尤其成问题,因为它严重、慢性且对简单镇痛药有抗性。这种疾病影响2%至3%的人口,给医疗保健系统带来高昂成本,对患者个人来说具有毁灭性。神经性疼痛的诊断主要基于病史(如潜在疾病和独特的疼痛性质)以及体格检查结果(如感觉障碍模式);然而,有时一些检查可能会有所帮助。重要的病理生理机制包括钠通道和钙通道上调、脊髓兴奋性过高、下行易化以及异常的交感 - 躯体神经系统相互作用。治疗通常是姑息性的,包括保守的非药物疗法、药物和更具侵入性的干预措施(如脊髓刺激)。个体化治疗需要考虑神经性疼痛的功能影响(如抑郁、残疾)以及持续评估、患者教育、安抚和专科转诊。我们提出一种具有最有利风险效益特征的初级保健治疗算法,包括外用利多卡因、加巴喷丁、普瑞巴林、三环类抗抑郁药、5-羟色胺 - 去甲肾上腺素再摄取抑制剂、曲马多和阿片类药物。神经性疼痛的研究和治疗领域尚处于发展初期,有许多未实现的目标。未来几年,预计神经性疼痛的基础和临床科学将取得一些进展,这将为持续遭受这种致残性疾病困扰的患者提供新的、更好的治疗方法。

相似文献

1
Neuropathic pain: a practical guide for the clinician.
CMAJ. 2006 Aug 1;175(3):265-75. doi: 10.1503/cmaj.060146.
2
Elucidation of pathophysiology and treatment of neuropathic pain.
Cent Nerv Syst Agents Med Chem. 2012 Dec;12(4):304-14. doi: 10.2174/187152412803760645.
3
Mechanisms and treatment of neuropathic pain.
Cent Nerv Syst Agents Med Chem. 2009 Mar;9(1):71-8. doi: 10.2174/187152409787601932.
4
Neuropathic pain: principles of diagnosis and treatment.
Mayo Clin Proc. 2015 Apr;90(4):532-45. doi: 10.1016/j.mayocp.2015.01.018.
5
Pharmacotherapy for neuropathic pain.
Pain Pract. 2006 Mar;6(1):27-33. doi: 10.1111/j.1533-2500.2006.00055.x.
6
Management of neuropathic pain.
Curr Opin Support Palliat Care. 2007 Aug;1(2):126-31. doi: 10.1097/SPC.0b013e3282eeb45f.
7
Current treatment options in neuropathic pain.
Curr Opin Investig Drugs. 2002 Mar;3(3):441-8.
8
Pharmacology and treatment of neuropathic pains.
Curr Opin Neurol. 2009 Oct;22(5):467-74. doi: 10.1097/WCO.0b013e3283311e13.
9
Medications for neuropathic pain: current trends.
Neurol Sci. 2006 May;27 Suppl 2:S183-9. doi: 10.1007/s10072-006-0598-7.
10
[Pharmacological treatment of neuropathic pain].
Rev Neurol (Paris). 1992;148(8-9):521-31.

引用本文的文献

1
Chronic pain selectively reduces the motivation to work for remifentanil but not food reward.
Pain. 2025 May 13;166(9):e212-e232. doi: 10.1097/j.pain.0000000000003606.
2
A meta-analysis of modern neuro-stimulation modalities-Advances in neuro-stimulation techniques.
Surg Neurol Int. 2025 Apr 25;16:146. doi: 10.25259/SNI_656_2024. eCollection 2025.
4
Evaluating cytidine, uridine, and gabapentin combinations for pain modulation and p-CREB expression in neuropathic model.
Future Sci OA. 2025 Dec;11(1):2483137. doi: 10.1080/20565623.2025.2483137. Epub 2025 Mar 31.
7
Neuropathic pain, antidepressant drugs, and inflammation: a narrative review.
J Anesth Analg Crit Care. 2024 Sep 27;4(1):67. doi: 10.1186/s44158-024-00204-z.
8
Diabetic Neuropathic Pain and Circadian Rhythm: A Future Direction Worthy of Study.
J Pain Res. 2024 Sep 16;17:3005-3020. doi: 10.2147/JPR.S467249. eCollection 2024.
10
The role of walking exercise on axonal regrowth and neuropathic pain markers in dorsal root ganglion after sciatic nerve injury.
J Exerc Rehabil. 2023 Dec 26;19(6):320-326. doi: 10.12965/jer.2346522.261. eCollection 2023 Dec.

本文引用的文献

1
Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy.
J Clin Neuromuscul Dis. 2001 Dec;3(2):53-62. doi: 10.1097/00131402-200112000-00002.
3
Pregabalin: a new neuromodulator with broad therapeutic indications.
Ann Pharmacother. 2005 Dec;39(12):2029-37. doi: 10.1345/aph.1G078. Epub 2005 Nov 15.
5
Combination pharmacotherapy for neuropathic pain: current evidence and future directions.
Expert Rev Neurother. 2005 Nov;5(6):823-30. doi: 10.1586/14737175.5.6.823.
6
7
Methadone in the management of intractable neuropathic noncancer pain.
Can J Neurol Sci. 2005 Aug;32(3):340-3. doi: 10.1017/s0317167100004236.
8
Algorithm for neuropathic pain treatment: an evidence based proposal.
Pain. 2005 Dec 5;118(3):289-305. doi: 10.1016/j.pain.2005.08.013. Epub 2005 Oct 6.
9
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
Neurology. 2005 Sep 27;65(6):812-9. doi: 10.1212/01.wnl.0000176753.45410.8b.
10
A review of the use of methadone for the treatment of chronic noncancer pain.
Pain Res Manag. 2005 Autumn;10(3):133-44. doi: 10.1155/2005/286713.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验